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Abstract
Background: Chronic diseases, represented mainly by cardiovascular disease (CVD) and cancer, are
increasing in developing countries and account for 53% of chronic diseases in Argentina. There is strong
evidence that a reduction of 50% of the deaths due to CVD can be attributed to a reduction in smoking,
hypertension and hypercholesterolemia. Generalized cost-effectiveness analysis (GCE) is a methodology
designed by WHO to inform decision makers about the extent to which current or new interventions
represent an efficient use of resources. We aimed to use GCE analysis to identify the most efficient
interventions to decrease CVD.
Methods:  Six individual interventions (treatment of hypertension, hypercholesterolemia, smoking
cessation and combined clinical strategies to reduce the 10 year CVD Risk) and two population-based
interventions (cooperation between government, consumer associations and bakery chambers to reduce
salt in bread, and mass education strategies to reduce hypertension, hypercholesterolemia and obesity)
were selected for analysis. Estimates of effectiveness were entered into age and sex specific models to
predict their impact in terms of age-weighted and discounted DALYs saved (disability-adjusted life years).
To translate the age- and sex-adjusted incidence of CVD events into health changes, we used risk model
software developed by WHO (PopMod). Costs of services were measured in Argentine pesos, and
discounted at an annual rate of 3%. Different budgetary impact scenarios were explored.
Results: The average cost-effectiveness ratio in argentine pesos (ARS$) per DALY for the different
interventions were: (i) less salt in bread $151; (ii) mass media campaign $547; (iii) combination drug
therapy provided to subjects with a 20%, 10% and 5% global CVD risk, $3,599, $4,113 and $4,533,
respectively; (iv) high blood pressure (HBP) lowering therapy $7,716; (v) tobacco cessation with
bupropion $ 33,563; and (iv) high-cholesterol lowering therapy with statins $ 70,994.
Conclusion: Against a threshold of average per capita income in Argentina, the two selected population-
based interventions (lowering salt intake and health education through mass-media campaigns) plus the
modified polypill strategy targeting people with a 20% or greater risk were cost-effective. Use of this
methodology in developing countries can make resource-allocation decisions less intuitive and more
driven by evidence.
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Background
Chronic diseases – mainly CVD, cancer, chronic respira-
tory diseases and diabetes – were estimated to have caused
over 60% of all deaths globally in 2005, of which more
than 80% occurred in low and middle-income countries;
almost half of these deaths will occur in people younger
than 70 years old (compared to only 27% from this age
group in high-income countries). It has been projected
that by 2015, 41 million people will die from chronic dis-
eases if there are no concerted efforts in prevention and
treatment.[1]
In Argentina, chronic diseases likewise account for more
than 50% of the overall morbidity and mortality. From a
total of 285,941 deaths in 2004, CVD accounted for
93,972 deaths, with a coronary heart disease age-adjusted
incidence of 360/100000 in men and 80/100000 in
women and a stroke age adjusted incidence of 120/
100000 in men and 75/100000 in women, a pattern sim-
ilarly found in other upper-middle income countries. [2]
In common with many other Latin American countries,
Argentina falls into an intermediate mortality group
where the main risk factors for disease are hypertension,
an elevated body mass index, alcohol abuse and smoking.
[3] Primary data describing the prevalence and distribu-
tion of cardiovascular risk factors in the city of Buenos
Aires has recently been obtained through two different
population-based sources: the 2004 Ministry of Health
National Risk Factor Survey [4]; and the Cardiovascular
Risk Factor Multiple Evaluation in Latin America (CAR-
MELA) [5]. The former surveyed a probabilistic sample of
almost 50,000 households from all Argentine districts to
detect risk factors, and the latter assessed the prevalence of
cardiovascular risk factors and common carotid intima-
media wall thickness distributions in a probabilistic sam-
ple of individuals living in 7 cities in Latin American,
including Buenos Aires.
The WHO recently addressed the importance of chronic
disease prevention as a neglected health issue in low- and
middle-income countries; achievement of the global goal
to reduce chronic disease death rates by 2% every year
would avert 36 million deaths between 2005 and 2015.
[6,7] Achieving this target would also save almost 10% of
the expected loss in national income in these settings[8]
There is strong evidence that a 50% reduction in cardio-
vascular deaths can be attributable to the reduction of just
three modifiable risk factors, namely tobacco consump-
tion, high blood pressure and elevated cholesterol [8]
Moreover, at least 75% of CVD can be explained by more
proximal risk factors like unhealthy diet, low physical
activity and tobacco consumption.
Most CVDs are preventable and there is evidence that sup-
ports the effectiveness of interventions to reduce the bur-
den of CVD through strategies that reduce risk factors.
Unfortunately, strategies to manage cardiovascular condi-
tions have been largely developed for high-income coun-
tries which may not be affordable to most of the
developing world. [9,10] The health resource allocation
decision process is usually empirical and driven by politi-
cal, social or financial issues. The utilization of scientific
evidence related to the economic impact of the interven-
tions to set health priorities and define public coverage
policies is uncommon in developing countries. Although
there has been widespread recognition of the benefit of
cost-effectiveness evaluation to inform national health
system priority setting, its potential has not been realized
in the vast majority of countries. We identified in a quali-
tative study conducted with Argentine healthcare decision
makers that even though economic considerations to pri-
oritize resource allocation were increasingly accepted, and
boosted after the recent financial crisis, the use and appli-
cation of economic evaluations was very poor and
restricted to a limited handful of cases. [11]
Cost-effective interventions to prevent CVD in developing
countries do exist, but have not been widely applied. Spe-
cifically, population and community-based interventions
appear to be highly cost-effective when they reach large
populations, address high mortality and morbidity dis-
eases, and include multi-level integrated efforts. Interven-
tions targeting individuals, especially high cardiovascular
risk subjects, are also cost-effective but usually require
clinical involvement and more resources. Moreover,
recent studies have consistently shown the cost-effective-
ness of interventions that lower the burden of CVD in
developing countries. [12,13]
Different types of cost-effectiveness analyses are available
to evaluate packages of interventions in terms of their
cost-effectiveness. Generalized Cost-Effectiveness (GCE)
analysis is a methodology designed by the WHO to evalu-
ate the current and potential coverage of health interven-
tions in order to improve allocative efficiency and to
facilitate policy makers' ability to make informed deci-
sions about health resource allocation. [14] Following a
request in 2005 by the Secretary of Health of the city of
Buenos Aires, the aim of this study is to develop a decision
making framework based on GCE methodology to help
policy makers identify the most cost-effective interven-
tions to diminish the burden of CVD in Buenos Aires,
Argentina.
Methods
Study population and perspective
Buenos Aires is the capital city of Argentina. According to
the last national census (2001) it has a population of
3,053,030 of which, 26.5% rely on public health services
alone while the majority has supplementary health careCost Effectiveness and Resource Allocation 2009, 7:10 http://www.resource-allocation.com/content/7/1/10
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coverage from social security or private health insurance
plans. The public health infrastructure of Buenos Aires is
composed of 66 primary health care centers, 33 hospitals
and 3,200 primary health care professionals, 50% of them
being primary care physicians.
We incorporated the perspective of the public sector of the
City of Buenos Aires. Because health care for the unin-
sured is a primary responsibility of the local government
through the public healthcare network, this study aimed
to reflect the cost-effectiveness and budgetary impact of
providing individual interventions to the uninsured pop-
ulation specifically. In contrast, the population-based
interventions were calculated as being delivered to the
whole population regardless of their insurance status.
Definition and selection of interventions
A total of eight population-based and individual primary
prevention interventions were selected to evaluate their
impact over a 10 year period. The interventions were
selected based on their common use as primary preven-
tions of CVD and evidence of efficacy and effectiveness.
The interventions had also been already selected in a pre-
vious landmark study [12].
Population-based interventions
1) Intervention to Reduce Salt Intake: Program involved
the cooperation between Government, consumer associa-
tions and the Bakery Chambers to reduce 1 gram of salt
per 100 grams of bread. Argentina has a consumption of
12 grams of salt per day, 3.4 grams coming from bread.
Local experiences showed that it is possible to reduce the
amount of salt in bread without being detected as less pal-
atable. At present, there is a pilot training program imple-
mented in selected cities in Argentina to make bakers
reduce salt in bread by using special salt dispensers. [15]
This intervention could imply a population-wide reduc-
tion of 1.33 mmHg of systolic blood pressure per person
(SBP) and 1% of the population attributable risk (PAR) of
coronary heart disease (CHD) and stroke. [16]
2) Public Education through mass media: Health educa-
tion through broadcast and print media promoting
healthy habits, low fat diet and low salt consumption. A
meta-analysis of community-based interventions through
mass media campaign, showed a decrease of 1.83 mmHg
of SBP in SBP and a 0.02 mm/l in cholesterol (t), implying
a reduction of 2% of the PAR of CHD and stroke. [17]
Individual Interventions
Six interventions were clinical interventions targeted
towards the uninsured (26.5% of the population of Bue-
nos Aires).
1) Individual treatment of high blood pressure: Interven-
tion involved lifestyle change promotion and pharmaco-
logical therapy to achieve blood pressure control (SBP/
DBP less than 140/90). In order to conduct the GCE anal-
ysis we assumed that 40% of the population would take
one drug, 40% at least two drugs and 20% three or more
drugs. The drugs and daily doses evaluated were hydro-
chlorothiazide (25 mg), atenolol (50 mg) and enalapril
(10 mg), the same efficacy for each drug category was also
assumed Analysis indicated that this interventions, with a
50% rate of disease detection and drug compliance indi-
cated by the Canadian Hypertension Guidelines, would
reduce PAR of CVD and stroke by 8%.[18]
2) Individual treatment of high cholesterol: Promotion of
low-cholesterol diet and statin use (atorvastine 10 mg) to
achieve a Cholesterol (t) target of less than 240 mg/dl,
(6.2 mm/l) provides an estimated reduction of 8% of the
PAR of CHD and stroke [19] a 50% detection and drug
compliance rate according to ATP III. [20]
3) Individual tobacco cessation therapy: Drug therapy
with bupropion for a 2-month period (300 mg per day)
results in an estimated reduction of 4% of the PAR of
CHD and stroke. [21] According to a recent national sur-
vey of tobacco prevalence [22] only 13% of total smokers
in Argentina were willing to quit smoking and therefore
are considered the target population of the intervention.
4) Treatment based on a population absolute risk
approach (modified polypill strategy): Pharmacological
therapy with thiazides 25 mg, enalapril 10 mg, atorvasta-
tin 10 mg and aspirin 100 mg prescribed to people with
an estimated combined risk of a cardiovascular event over
the next decade above a given threshold (>5%, >10% or
>20%) implying a reduction of PAR of CHD and stroke of
15%, 40% and 60% for each risk group, respectively. [23]
We assumed a 50% compliance rate in those with a 10
year risk of 5% and 10%, and 80% compliance in those
with a 20% risk. The prevalence and values of high blood
pressure, high cholesterol and smoking in Buenos Aires
were obtained from recent study estimates [4,5]. The
number of subjects in each risk strata was estimated by
using the beta coefficients from the Framingham Heart
Study. [24]
Modeling of intervention effects
Our analytic model was based on the WHO-CHOICE
methodology. This approach entails lifting the constraints
of the current mix of interventions, using a null scenario
of no costs and no interventions as a starting point to esti-
mate allocative – as opposed to productive/technical –
efficiency in the health sector.[14] The null scenario was
calculated taking into account that the only individual
intervention of those selected, currently provided by theCost Effectiveness and Resource Allocation 2009, 7:10 http://www.resource-allocation.com/content/7/1/10
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Secretary of Health to the uninsured, is hypertensive ther-
apy, while statins and bupropion are not yet covered by
the public health care system.
In order to estimate the reduction in disease burden
related to the reduction of CVD, we needed a model to
predict the burden associated with specific diseases or risk
factors to develop disease. In table 1 we show base-case
estimates of the relative risks (RR) of CHD and stroke and
its respective sources. We used Population Attributable
Risk (PAR) as a measure of impact of each risk factor on
the incidence of CHD and Stroke where
Then, with the estimate of the Relative Risk (RR) of the
intervention and the PAR, we calculated the percent PAR
reduction of CHD and Stroke as a consequence of the
intervention as follows:
Finally, the model translated these changes in cardiovas-
cular risk events specific for age and sex (Δ PAR before and
after the intervention) into changes in population health,
quantified by number of DALYs averted. Effect sizes and
joint effect of interventions used in the analysis were
based on systematic reviews of randomized trials and
meta-analysis, when possible. Intervention effects with
their corresponding relative risks (RR) estimates are
shown in Table 2.
To translate changes in the risk of age and sex specific CVD
events into changes in population health quantified in
terms of DALYs, we used a standard multi-state modeling
tool develop by the WHO-CHOICE group, PopMod. In
this model, health effects are estimated by tracing what
would happen to each age and sex cohort of a given pop-
ulation over 100 years with and without the interven-
tion.[14] PoPMod is a four-state population model
simulating the evolution of a population split into 4 dif-
ferent health states: people who have one condition (i.e.
CHD), people who have another condition (i.e. Stroke)
people who have both conditions (i.e. CHD and Stroke),
and people who have none of the above but are at risk.
Births and deaths are also included and transition rates
such as incidence, remission, and mortality, govern move-
ments between states.
Transitional probabilities and disability weights of CVD
and stroke were obtained from WHO-Choice CVD tem-
plate that is based on Framingham data. The entire popu-
lation is subject to background mortality and morbidity,
which are assumed to be independent of the CVD states
explicitly modeled. In summary, this model projects the
effect of interventions on the aggregate healthy years of
life lived by a population, combining incidence, preva-
lence, and mortality and estimates of disease severity with
information on intervention coverage and effectiveness.
[25].
Intervention Costs
Costs included program-level expenses associated with
management of the interventions (i.e., administration,
training and information dissemination by multiple
media sources) and patient-level costs (i.e. primary care
visits, ancillary tests and drugs). Potential cost-savings
related to an event prevented by an intervention were not
incorporated because the counterfactual or comparator
situation is one without intervention (null scenario). The
quantities of each input required were assessed and mul-
tiplied by the unit price of each input for the 10 year-inter-
vention implementation period. For each program cost
the quantities of required inputs were identified from sim-
ilar programs conducted in the City of Buenos Aires or
from expert opinion where necessary. The quantity of
patient-level resource inputs for each intervention (i.e.
inpatient hospital days, doctor visits, tests, drugs) were
identified from local or international published data
where available or from expert opinion. Costs of drugs
were calculated using a mix of blood pressure lowering
drugs composed of 50% thiazides, 20% beta blockers,
20% ACE inhibitors and 10% calcium channels blockers,
according to a recently published study.[26] Cost of blood
PAR Prevalence relative risk prevalence relative ris :( ) / ( ( ×− ×    1 k k −+ 11 ))
Change in PAR fraction PAR fraction RF PAR fraction RR o            =− × () ( f f intervention  )
Table 1: Relative Risks for Coronary Heart Disease (CHD) and Stroke for different conditions
Risk factor CHD RR Reference Stroke
RR
Reference
Hypertension 1.91 [33] 4 [34]
Tobacco use 1.68 [24] 2 [35]
Hypercholesterolemia 2.5 1 [36]
More than 5% CVD global risk * 8.84 [4,5] 8.84 [4]
More than 10% CVD global risk* 13.12 13.12
More than 20% CVD global risk* 18.8 18.8
CVD: Cardiovascular disease.
* Local Population-based age and sex specific prevalence of cardiovascular risk factors and its observed distribution were used. Then, we derived 
global CVD risk using Framingham Risk Equation (25) to estimate CVD risk in each stratum (more than 5%, more an 10% and more than 20%)Cost Effectiveness and Resource Allocation 2009, 7:10 http://www.resource-allocation.com/content/7/1/10
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pressure lowering drugs, atorvastatine and bupropion,
other input costs and expense data, as well as other cost
data, were extracted from the purchase database of the
Health Ministry of Buenos Aires City Government and the
Institute of Clinical Effectiveness and Health Policy Unit
Costs database. A list of the costs and sources of the inter-
ventions and selected health events is depicted in Table 3.
Except when explicitly stated, additional costs (i.e. a pro-
gram to identify high cardiovascular risk people), costs
related to labor, equipment, capital, overhead or joint
costs were regarded as existing, ongoing, or common to all
interventions and therefore were excluded in the calcula-
tion. We excluded costs of accessing health interventions
that would include the resources used by patients and
their families to obtain an intervention (transport costs)
as well as productivity gains or losses, as the study was
conducted from a purchaser perspective. All costs were
calculated in Argentine pesos for the year 2005 (ARS
$3.01 = US $1 exchange rate on March, 2005). The dis-
counting of long term costs were performed at a 3% rate.
Calculating cost-effectiveness
Cost-effectiveness analysis generally considers the costs
and effects of adding new interventions to current practice
or the cost of replacing an existing intervention with
another targeting the same condition. Here we evaluated
the proposed interventions by first considering what
would happen to the population health if they all ceased
to be implemented today. This is the null or 'do nothing'
scenario. Average cost-effectiveness ratios were then calcu-
lated for each intervention by combining the information
on total costs with information on the total health effects
in terms of DALYs averted. DALYs are age-weighted and
discounted at 3% per annum. To estimate the financial
impact of conducting the interventions at different budget
scenarios, costs were then compared with their health
gains to identify the most cost-effective set of interven-
tions at different levels of resource availability.
Table 2: Relative risks of proposed interventions
Interventions RR (point estimate used in the model) Reference source
Population-based
Health education through Mass Media 0.98 (1) [17]
Reduction of salt in bread through voluntary agreement 0.99 (2) [16]
Individual (clinical)
Pharmacological Treatment of High Blood Pressure 0.82 [37]
Pharmacological Treatment of High Cholesterol 0.95 [19]
Tobacco cessation therapy with bupropion 0.8 [21]
Combined therapy for patients with> 5% global risk 0.12 (3) [23]
Combined therapy to > 10% global risk
Combined therapy to > 20% global risk
(1) The translation of reduction in mmHg and cholesterol mg reported by the intervention to relative risk was done using Framingham Risk 
Equations from Wilson et al, Circulation 1998 [24].
(2) Average population bread consumption was estimated from the Agricultural and Food Secretariat. The average amount of salt in bread was 
obtained from a survey from the National Institute of Industrial Technology (INTI 2005). Then, we applied the same equation as in (1) to transform 
mmHg decreases in relative risk reduction
(3) We subtracted the folic acid effect from the polypill paper due to its lack of consistent evidence of efficacy
Population health effects due to the interventions were modeled simulating population specific for age and sex with the observed baseline values of 
cardiovascular risk and the observed distribution of risk factors drawn from local data [4,5]
Table 3: Interventions and related health events summary costs
Event cost per hospital admission ARS $
Coronary Heart Disease 2,879
Stroke 1,682
Total intervention cost per year
Health education through Mass Media1 634,069
Less salt in bread2 87,471
Yearly cost per person3
Hypertension treatment 39.54
High Cholesterol treatment 70.19
Bupropion treatment for tobacco cessation 109.73
Modified Polypill strategy 92.71
1. Ten years duration of campaign, more intensive during the first two 
years and with periodic reinforcement over the ten-tear period.
2. Assuming 54 meeting of 30 bakers each (aprox. 800-600 bakers). 
These meetings will be carried out during the first two years with 
reinforcement meetings for years fifth and sixth and ninth and tenth.
3. Includes health center visits, drug and lab test costs.
Cost of blood pressure lowering drugs, atorvastatine and bupropion 
as well as other input costs and charges data were extracted from the 
purchase data of the Health Ministry of Buenos Aires City 
Government (available at http://www.buenosaires.gov.ar/areas/
hacienda/compras/ comprassalud, 2005). Other cost data were 
obtained from the Health Care Costs Database by the Institute of 
Clinical Effectiveness and Health Policy (accessed at http://
www.iecs.org.ar/ Base de Datos de Costos Sanitarios Argentinos).Cost Effectiveness and Resource Allocation 2009, 7:10 http://www.resource-allocation.com/content/7/1/10
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Sensitivity analysis
Selected one-way sensitivity analyses were undertaken to
assess the effects of uncertainty in the assumptions on the
baseline levels of risks and effect sizes of interventions.
The analysis was conducted taking into account an uncer-
tainty of 20% around the central estimate of each variable.
In addition, an undiscounted scenario was considered for
costs and DALYs, and a non age-weighted scenario was
also analyzed for DALYs.
Results
The prevalence of high blood pressure, high cholesterol
and smoking, as well as the percentage of target popula-
tion in each 10-year CV risk strata (>5%, >10%, and
>20%) in Buenos Aires can be seen in Table 4. During
2004, there were 1,338 hospital admissions with a diag-
nosis of CHD and 977 with a diagnosis of stroke at an
average cost per admission of ARS $2,879 and ARS $1,682
for CHD and stroke, respectively
Table 5 gives the total annual costs and, total annual
health effects in terms of DALYs averted (age-weighted
and 3% discounted, and non-age weighted and undis-
counted) and the average cost-effectiveness ratio for each
of the 8 distinct interventions. Concerning specific inter-
ventions, the strategy of lowering salt intake in the popu-
lation through reducing salt in bread was found to be the
most cost-effective (ARS $151 per DALY averted), fol-
lowed by health education through mass-media cam-
paign (ARS $547 per DALY averted) and the modified
polypill strategy. This pharmacologic approach to patients
with an estimated combined risk of a cardiovascular event
over the next decade above 20%, 10% or 5% showed a
cost-effectiveness ratio of ARS $3,599, $4,113 and $4,533
per DALY averted. respectively. Because these interven-
tions are mutually exclusive, only one of the three cut-off
points can be selectedOn the other hand, interventions
targeted at individual risk factors like high blood pressure
control with antihypertensive drugs, treatment of high
cholesterol with a statin and tobacco cessation therapy
with bupropion, ranked lower than the previous three and
were dominated, as shown in Figure 1. Lowering choles-
terol with statins and tobacco cessation with bupropion
were not found to be cost-effective, in part because statins
and bupropion are much more expensive than HBP low-
ering drugs and also because as they are not currently cov-
ered, the government does not usually exert its purchasing
power to get lower prices. In addition, and in accordance
with local surveys as mentioned above, as long as we
assumed that only 13% of the population of smokers
would be willing to quit smoking each year and conse-
quently start on a program, the population impact of
tobacco cessation therapy was much smaller than
expected.
Results of sensitivity analysis
In order to estimate the budget impact of the three most
cost-effective interventions, we analyzed the Buenos Aires
Health Ministry annual operative budget. Total annual
budget for the year 2004 was ARS $1.2 billion. After
reviewing all budget item lines, most of them were consid-
ered rigid in terms of the difficulties to shift money from
one budget line to another (i.e. labor costs, facilities,
equipment, capital, land, overhead, etc.). Nevertheless,
we were able to identify a "flexible" budget of ARS $106
million, representing about 8% of the total budget. Subse-
quently two budget reallocation scenarios were built that
considered a small part of the flexible budget to finance
the interventions until the money was exhausted. The first
scenario would use 10% of this flexible budget (ARS
$10,600,000) while the second scenario would use 20%
(ARS $21,300,000).
As shown in Table 6, the reallocation of 10% of the flexi-
ble budget to this selected intervention set could finance
the two population-based interventions, namely less salt
in bread through negotiations and regulations with the
Bakery Association and a mass-media campaign to edu-
cate people on healthy habits, low fat diet and low salt
consumption (averting 250 DALYs per 100,000 subjects
over 10 years); the remaining 9 millions could be used to
start financing programs to detect, diagnose and treat sub-
jects with high cardiovascular risk, saving additional
DALYs in this population. The reallocation of 20% of the
budget (and assuming non-divisibility of clinical inter-
ventions) could almost quadruple DALYs averted, ena-
bling the addition of the modified polypill strategy to
subjects with an estimated cardiovascular risk above 20%.
This last outcome would be reached using less than 3% of
the total annual operative budget of the district.
Discussion
In the context of the escalating burden of chronic disease
in developing countries, this study set out to provide local
Table 4: Prevalence of Cardiovascular risk factors and risk strata 
in Buenos Aires by gender (1)
Prevalence Males/Females (%)
High Blood Pressure 40/26
High Cholesterol 22/22
Smoking 40/35




(1) Uninsured population covered by Buenos Aires city public 
healthcare network (approximately 800.000 persons)
(2) % of subjects in each cardiovascular risk strata were derived from 
Framingham equations using risk factor values obtained from 
population surveys of Buenos Aires, ArgentinaCost Effectiveness and Resource Allocation 2009, 7:10 http://www.resource-allocation.com/content/7/1/10
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decision-makers with information comparing the relative
costs and health effects of interventions for preventing
CVD, and in so doing focus policy debate concerning the
trade-offs or opportunity costs of financing one interven-
tion over another. Establishing the cost-effectiveness of
chronic disease interventions in developing country con-
texts is not straightforward, however, owing to the paucity
of existing information and evidence in these more
resource-constrained contexts, and also because there is
no universally agreed threshold for considering the cost-
effectiveness of an intervention to be 'too high' or 'right'.
What is acceptable to health and finance decision-makers
depends on the country context. The Disease Control Pri-
orities Project (DCPP), has identified several chronic dis-
ease interventions as cost-effective at a cost of below
$1,000 per DALY. [27] However, the affordability of inter-
ventions will vary significantly across countries, even
among a group of interventions believed to be cost-effec-
tive in the global sense. Moreover, sensitivity analysis
done as part of the CEA modeling for the DCPP showed
that the cost-effectiveness of public education campaigns
at the population level could be very good or far less favo-
rable depending on how much it cost to reach people
using a reasonable range of costs. In addition, even a very
inexpensive intervention might not be worth implement-
ing if it targets a chronic disease with low prevalence in a
given country or region.
In an earlier analysis that formed the basis for the present
exercise, Murray et al. [12] modeled selected population-
based and individual health interventions to lower high
blood pressure and high cholesterol in the epidemiologi-
cal contexts of developing countries. The authors found
that all interventions were highly cost-effective in the sub-
region of the Americas to which Argentina belongs.
More recently, Asaria et al., assessed the financial costs
and health effects of a voluntary reduction in the salt con-
Figure 1Cost Effectiveness and Resource Allocation 2009, 7:10 http://www.resource-allocation.com/content/7/1/10
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tent of processed foods by manufacturers plus a mass
media campaign to encourage dietary change in 23
selected low and middle income countries, including
Argentina. They estimated that a 15% reduction in dietary
salt intake in Argentina would save 60,000 lives over the
period 2006–2015 at a cost of US$ 0.14 per capita (equiv-
alent to ARS $1.2 million for a population the size of Bue-
nos Aires (3 million).[28] The addition of individual-level
interventions with a multi-drug regimen on the basis of
opportunistic contact with the health service, by contrast,
has been estimated at US$ 2.93 per capita in Argentina
(around ARS 25 million for the population of Buenos
Aires), but would save a further 50,000 lives over a 10-year
period. [29]
As compared to these previous studies [12,28], our inter-
vention to decrease salt intake, even though was aimed to
reduce salt only in bread instead of reducing salt in all
processed foods, had a similar cost-effectiveness ratio
than the Asaria's study (ARS $ 151 per DALY vs. ARS $ 202
per DALY). In regards to the intervention oriented to
reduce cardiovascular disease in subjects with different
cardiovascular risks, health gains in DALYs averted in our
study were remarkably similar to those reported by Mur-
ray et. al. for the same risk strata, although costs were
much higher, Consequently, cost per DALY saved for each
risk group was also higher in our study
In summary, the two selected population-based interven-
tions (lowering salt intake and health education through
mass-media campaigns) and the modified polypill strat-
egy targeting people above 20% of cardiovascular risk in
10 years were very cost-effective according to the thresh-
old adopted by WHO-CHOICE (an intervention that
saves one DALY for less than three times gross national
product (GNP) per capita is considered cost-effective,
while one that saves a DALY for less than GNP per capita
is deemed very cost-effecive). [30] As Argentina's GNP per
person in 2005 was ARS $ 13,728 (US$ 4,470) [31], esti-
mated CERs of each of these interventions fall well within
the 'very cost-effective' category. However, as mentioned
above, our results differ from those obtained in the afore-
mentioned regional analysis: concerning salt, both our
health impact and cost estimates are appreciably lower
than those summarized above, partly because we only
included a series of one-off meetings with bread makers,
Table 5: Costs, effects and cost-effectiveness of interventions analyzed















Less salt in bread $ 87,471 579 713 1,107 $ 151
Mass media 
campaign
$ 634,069 1,158 1,426 2,213 $ 547
Combined therapy 
20% global CV risk
$ 23,533,467 6,539 8,033 12,468 $ 3,599
Combined therapy 
10% global CV risk
$ 46,323,335 11,263 13,913 2,163 $ 4,113
Combined therapy 
5% global CV risk
$ 63,893,600 14,095 17,409 2,706 $ 4,533
HBP lowering 
therapy




$ 12,317,628 367 449 697 $ 33,563
High-chol lowering 
with statins
$ 40,253,626 567 712 1,087 $ 70,994
Table 6: Purchasing options using flexible budget reallocation scenarios to finance interventions
Budget per year ARS $ Interventions Cost per year period
(ARS $)
DALYs averted DALYs averted per 100.00 population
10.6 millions
(10% of the budget)
• Less salt in bread
• Mass media campaign
$ 721,540 1,737 250 Dalys
21.3 millions
(20% of the budget)
• Mass media campaign
• Less salt in bread
• CV risk 20%
24.2 millions 7,118 1050 Dalys
For this table, we assumed non-divisibility of the potential programmes.Cost Effectiveness and Resource Allocation 2009, 7:10 http://www.resource-allocation.com/content/7/1/10
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and also because we used a lower effect size. Concerning
the modified polypill strategy, effects are also less than
predicted by the regional models, but our cost estimates
are considerably higher, which reflects the fact that key
intervention resource inputs in Buenos Aires – including
human resources, secondary care and drugs – are much
more expensive than the regional average.
According to estimates from the Global Burden of Disease
project, [32] the estimated burden in a single year due to
HBP, high cholesterol and high body mass index (BMI)
for America B countries add up to 5.47 million DALYs in
men and 4.56 million in women, equivalent to 23,304
per 100,000 people over a 10-year period. Therefore, the
implementation of these three integrated interventions
(less salt in bread, mass media campaign to promote
healthy lifestyles and drugs to prevent CVD in high-risk
patients) in the Buenos Aires metropolitan area would
save 1,200 DALYs per 100,000 individuals and would
account for a 5% reduction in the burden of CVD. More-
over, considering that our hospital costs for acute myocar-
dial infarction and stroke over 10 years were only in the
range of ARS $2.1 million (discounted at a 3% annual
rate), and the overall cost estimate for the selected inter-
ventions would be only 10% of the cost of acute events
(ARS $205 million), these interventions would be cost-
saving if the counterfactual scenario had been what the
government is actually spending on the care of cardiovas-
cular disease.
Conclusion
Overall, evidence exists to conclude that there are impor-
tant economic as well as clinical consequences of CVD,
consequences that are not only important to the individ-
ual and his/her family but also to the economy at large. At
the same time, there are severe gaps in the evidence that
call for more research into the avoidable burden of CVD,
and in particular for developing countries [33-37]. Taking
into account the increasing burden of CVD in Argentina,
ranking first over the last decades as a cause of mortality
and morbidity, urgent action is needed to convince policy
makers about the high yield of integrated interventions
like the ones evaluated above.
Finally, although cost-effectiveness should be one of the
key inputs for policy makers to make resource-allocation
informed decisions, other criteria are usually taken into
account, like equity, social acceptance, intuition, prior
decisions, and healthcare infrastructure needed to
"accommodate" new interventions, not mentioning less
transparent criteria like personal interest and corruption.
Nevertheless, this framework aims to help policy makers
to make informed resource-allocation decisions when
making choices to reduce the burden of CVD, especially in
middle-income developing countries like Argentina.
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